Topics

Sunovion Highlights Data from Its Psychiatry Portfolio at the 2019 American Psychiatric Association Annual Meeting

08:00 EDT 2 May 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it will present clinical and health economic outcomes data from its psychiatry portfolio and pipeline of potential medicines for patients living with schizophr...

Other Sources for this Article

Kirsten Fallon
Senior Manager, Portfolio Communications
Sunovion Pharmaceuticals Inc.
774-369-7116
kirsten.fallon@sunovion.com

NEXT ARTICLE

More From BioPortfolio on "Sunovion Highlights Data from Its Psychiatry Portfolio at the 2019 American Psychiatric Association Annual Meeting"

Quick Search

Relevant Topics

Mental Health
Adhd Anorexia Depression Dyslexia Mental Health Psychiatry Schizophrenia Stress Mental health, although not being as obvious as physical health, is very important, causing great unhappiness to those affected, causing add...

Schizophrenia
Schizophrenia is a common  serious long-term mental health condition that affects 5 in 1000 in the UK. It causes a range of different psychological symptoms; hallucinations, delusions, muddled thoughts based on the hallucinations or delusions and ch...

Bipolar Disorders
Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Over half of Bipolar cases develops before the age of 25. Bipolar ...